Asset Details
Do you wish to reserve the book?
Comparisons of pharmacokinetics of glimepiride in combination with Ojeok-san versus glimepiride alone: an open-label, one-sequence, two-treatment controlled clinical study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comparisons of pharmacokinetics of glimepiride in combination with Ojeok-san versus glimepiride alone: an open-label, one-sequence, two-treatment controlled clinical study
Do you wish to request the book?
Comparisons of pharmacokinetics of glimepiride in combination with Ojeok-san versus glimepiride alone: an open-label, one-sequence, two-treatment controlled clinical study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Comparisons of pharmacokinetics of glimepiride in combination with Ojeok-san versus glimepiride alone: an open-label, one-sequence, two-treatment controlled clinical study
2025
Overview
Glimepiride remains a cost-effective antidiabetic treatment despite its potential risks. However, its interaction with traditional medicines like Ojeok-san (OJS), a commonly used herbal medication, warrants investigation. This open-label, fixed-sequence, two-period, two-treatment crossover study involved 17 healthy male volunteers. Subjects received glimepiride 4 mg once daily for 2 days in period 1, followed by OJS 4.35 g three times daily for 8 days, with concurrent glimepiride administration on the final two days in period 2. Co-administration of OJS with glimepiride resulted in pharmacokinetic changes. The mean area under the plasma concentration-time curve (AUC) from dosing to 24 h post-dosing (AUC
0–24 h
) of glimepiride decreased from 1283.53 ng∙h/mL to 1125.27 ng∙h/mL, and the mean maximum concentration (C
max
) reduced from 250.76 ng/mL to 209.38 ng/mL when compared to glimepiride alone. OJS co-administration also prolonged the median time to reach maximum concentration (T
max
) and half-life (t
1/2
). The study demonstrated pharmacokinetic interactions between glimepiride and OJS, showing reduced systemic exposure and altered elimination patterns of glimepiride during co-administration.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 692/700
/ Acids
/ Adult
/ Consent
/ Diabetes
/ Dosage
/ Drugs, Chinese Herbal - administration & dosage
/ Drugs, Chinese Herbal - pharmacokinetics
/ Enzymes
/ Glucose
/ Humanities and Social Sciences
/ Humans
/ Hypoglycemic Agents - administration & dosage
/ Hypoglycemic Agents - pharmacokinetics
/ Male
/ Medicine
/ Plasma
/ Science
/ Sulfonylurea Compounds - administration & dosage
